Apogee Therapeutics, Inc. Common Stock annual earnings per share (EPS) for fiscal TTM was $-4.44, a decrease of 5.2% from $-4.22 in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EPS (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Earnings Per Share (EPS) | $-4.44 | $-4.22 | $-3.30 | $-1.66 | $-0.79 |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EPS (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (EPS) | $-1.14 | $-1.06 | $-1.14 | $-1.11 | $-1.13 | $-0.95 | $-1.22 | $-0.86 | $-0.60 |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More APGE metrics: Revenue · Gross Profit · Operating Income · Net Income · EBITDA · Free Cash Flow · Shares Outstanding
All APGE financial statements → Interactive APGE charts →
About TickerBase · Data methodology & sources · Privacy · Terms